Mensinger Mike 4

Accession 0001415889-25-002819

CIK 0001674632other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 8:30 PM ET

Size

21.7 KB

Accession

0001415889-25-002819

Form 4

Period: 2025-01-31

Chief Product Officer

Transactions

Purchase
Common Stock
2025-01-31$17.00/sh+33,350$566,950→ 59,019 total
Conversion
Class B Common Stock Warrant (right to buy)
2025-01-31+10,575→ 10,575 total
Exercise: $0.02From: 2023-08-28Exp: 2033-08-27→ Common Stock (10,575 underlying)
Conversion
Common Stock
2025-01-31+15,107→ 15,107 total
Conversion
Series D Preferred Stock
2025-01-31−15,107→ 0 total
→ Common Stock (15,107 underlying)
Sale
Common Stock
2025-01-31$17.00/sh−13$221→ 25,669 total
Award
Employee Stock Option (right to buy)
2025-01-31+236,553→ 236,553 total
Exercise: $5.10Exp: 2033-09-13→ Common Stock (236,553 underlying)
Exercise of In-Money
Common Stock
2025-01-31$0.02/sh+10,575$212→ 25,682 total
Exercise of In-Money
Class B Common Stock Warrant (right to buy)
2025-01-31−10,575→ 0 total
Exercise: $0.02From: 2023-08-28Exp: 2033-08-27→ Common Stock (10,575 underlying)
Award
Employee Stock Option (right to buy)
2025-01-31+110,278→ 110,278 total
Exercise: $17.00Exp: 2025-01-28→ Common Stock (110,278 underlying)

Footnotes (7)

[F1]Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.
[F2]On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares.
[F3]The shares were purchased in the Issuer's initial public offering.
[F4]Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.
[F5]One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
[F6]Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
[F7]Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.

Documents

1 file

Beta Bionics, Inc.

CIK 0001674632

Entity typeother